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Introduction: Recent studies suggest that Alzheimer’s disease (AD) biomarker disclo-
sure has no discernable psychological impact on cognitively healthy persons. Far less is
known about how such results affect symptomatic individuals and their caregivers.
Methods: Randomized controlled trial of 82 mild cognitive impairment (MCI) patient
and caregiver dyads (total n = 164) to determine the effect of receiving amyloid
positron emission tomography results on understanding of, and perceived efficacy to
copewith, MCI over 52weeks of follow-up.
Results:Gains in the primary outcomes were not consistently observed. Amyloid neg-
ative patients reported greater perceived ambiguity regardingMCI at follow-up, while
moderate and sustained emotional distress was observed in patients, and to a lesser
extent, caregivers, of those who were amyloid positive. There was no corresponding
increase in depressive symptoms.
Discussion: These findings point to the possibility that both MCI patients and care-
givers may need emotional support after the disclosure of amyloid scan results.
KEYWORDS
amyloid positron emission tomography, biomarker disclosure, caregiving, ethics, mild cognitive
impairment
1 INTRODUCTION
Biomarker tests of Alzheimer’s disease (AD) pathology can provide
critical insights into the etiology of cognitive decline,1-3 and sharing
such information with patients and families affected by mild cognitive
impairment (MCI) could lessen their sense of ambiguity regarding the
syndrome.
We tested the hypotheses that, irrespective of scan results,
giving patients the opportunity to learn their brain amyloid sta-
tus would enhance understanding of and decrease perceived
ambiguity regarding MCI, and empower both patients with MCI
and their family caregivers to cope more effectively with its
challenges.
2 METHODS
2.1 Design and participants
The Return of Amyloid Imaging Scan Results (RAISR) Study enrolled
participants from the University of Pittsburgh Alzheimer Disease
Research Center (ADRC) between September 2014 and September
2018. Eligible participants and their family caregivers were allocated
as dyads in a 1:1 ratio to a scan group or comparison group (Figure 1).
Details of the study design and protocols for MCI education (compar-
ison group) and pre-testing counseling (scan group), amyloid positron
emission tomography (PET) results disclosure, and adverse eventmon-
itoring have been previously described.4-6 Briefly, we included patients
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with all MCI subtypes and excluded those with active untreated mood
disorders. Caregivers were 18 years of age or older. All participants
provided written informed consent and demonstrated decisional
capacity.
RAISR was approved by the University of Pittsburgh Institutional
Review Board and registered at ClinicalTrials.gov.
2.2 Intervention
Scan group dyads received pre-test counseling including content on
normal aging, MCI, and AD, amyloid PET, and information about the
limitations of knowledge to be gained. Participants were encouraged
to consider possible reactions to potential scan result scenarios before
deciding whether to proceed. Comparison group dyads received an
MCI education session with no option of amyloid PET. PET scans were
acquired using a standard florbetapir F18 injection protocol7 and rated
using a validated binary visual readmethod.8,9
The disclosure protocol included: verbal and visual presentations
of scan results using “significant amyloid buildup,” or lack thereof, to
describe positive and negative scans; short-term risk estimates for
conversion to AD; brain health information; and follow-up monitoring
instructions.4 Participantswere randomly assigned tooneof three clin-
ically licensed, formally trained results disclosers. Disclosure sessions
were audited for protocol adherence and participants’ comprehension
of information presented was verified.4
2.3 Primary outcomes
Outcomes measures were administered at baseline and weeks 4, 24,
and 52 post-disclosure (scan group) or MCI education session (com-
parison group). Objective knowledge of MCI was measured using the
MCI/AD Knowledge Assessment from the Risk Evaluation and Edu-
cation for Alzheimer’s Disease IV (REVEAL IV) protocol.10 Perceived
ambiguity about what MCI means was measured using the Illness
Coherence Subscale of the Revised Illness Perception Questionnaire
(IPQ-R).11 Self-efficacy for coping was measured by the Coping Self-
Efficacy Scale (CSE).12
2.4 Psychological safety
Depressive symptoms were measured by the Center for Epidemiolog-
ical Studies Depression Scale (CESD).13 State anxiety was measured
by the Spielberger State Anxiety Inventory (STAI).14 Emotional impact
was measured by the 15-item Impact of Event Scale (IES).15 The Dis-
tress and Positive Impact subscales of the Impact of Genetic Testing-
Alzheimer’s Disease (IGT-AD) were also administered,16 substituting
“test result” for “genetic test.”
2.5 Statistical analyses
Intention-to-treat (ITT) analyses of primary outcomeswere conducted
based on an a priori power analysis indicating that 40 subjects per
HIGHLIGHTS
∙ First randomized controlled trial of amyloid imaging
results disclosure inmild cognitive impairment (MCI).
∙ The vast majority of those who were eligible opted
to receive amyloid positron emission tomography with
results disclosure.
∙ Contrary to our hypothesis, learning one’s brain amyloid
status did not improve understanding of, or capacity to
copewith, the uncertainty of anMCI diagnosis.
∙ Rather, significant test-related distress was present in
amyloid positive patients and caregivers, with caregivers
feeling less able to cope with MCI after learning that it is
likely a prodrome to Alzheimer’s disease.
RESEARCH INCONTEXT
1. Systematic review: Searching combinations of the key-
words “amyloid imaging,” “mild cognitive impairment,”
and “ethics” yielded six observational studies of psycho-
logical reactions to disclosing amyloid imaging results
plus two reports of comprehension of amyloid imag-
ing results. These studies suggest that receiving amyloid
positron emission tomography (PET) results has little to
nopsychological impacton recipientsof such information.
2. Interpretation: This randomized controlled trial exam-
ined outcomes of distinct relevance to persons, and care
partners of those, living with the uncertainty of an mild
cognitive impairment (MCI) diagnosis. We tested the
hypothesis that amyloid PET results disclosure would
improve understanding of and self-efficacy for cop-
ing with the syndrome among MCI care dyads. These
hypotheses were not supported. Rather, we found that a
negative emotional response is possible.
3. Future Directions: Our findings suggest that MCI care
dyads may benefit from monitoring and emotional sup-
port after disclosure of biomarker test results.
group would yield 80% power to detect a medium effect size of
0.64 (from a behavioral science perspective) at a two-tailed signif-
icance level of .05. This estimation is conservative given RAISR’s
repeated measures design, which can detect effect sizes as small as
0.32.
After screening, transformations were applied to normalize skewed
residuals where encountered (eg, CESD, STAI). Group comparisons
of participant characteristics were performed using two-sample
t-tests (or Mann-Whitney U-tests) and chi-square tests (or Fisher
exact tests). Linear mixed modeling with fixed effects for group and








36 PT/34 CG completed 52-week follow-up33 PT/32 CG completed 52-week follow-up• 2 dyads missing 52-week data
119 patients screened and invited from the ADRC
37 patients excluded/declined
• 8 not meeting inclusion criteria
• 18 declined to participate
• 11 lost to contact
35 dyads completed 4-week follow-up
• 2 dyads missing 4-week data
39 dyads completed educational session
1 dyad withdrew due to lack of interest in 
assignment to comparison group
2 dyads dropped out
• 1 withdrawn due to enrollment in
medication trial that discloses Aβ status
• 1 withdrew due to patient health problems
35 PT/33 CG completed 24-week follow-up
• 1 dyad missing 24-week data
36 dyads completed 24-week follow-up
• 1 dyad missing 24-week data
1 dyad lost to contact
1 CG dropped out due to health problems
36 CP/35 CG completed results disclosure
• 1 dyad declined results
1 dyad dropped out due to dissatisfaction with 
delay in receiving results
1 CG withdrew due to lack of interest
42 dyads included in analysis40 dyads included in analysis
42 dyads to scan opportunity
39 PT/38 CG completed pre-test counseling
3 dyads dropped out
• 1 withdrew due to PT/CG relationship
• 1 lost to contact
• 1 withdrawn for not meeting eligibility criteria
1 CG withdrawn by PT
82 dyads (82 PT/82 CG) randomized/assigned*
37 patients completed scan
• 2 patients declined scan
37 PT/36 CG completed 4-week follow-up
40 dyads to comparison
F IGURE 1 Consort diagram. ADRC, Alzheimer Disease Research Center (University of Pittsburgh); PT, patient; CG, caregiver. *N= 12 patients
had previously undergone a research positron emission tomography (PET) amyloid scan under a protocol that precluded results disclosure. The
randomization process was overridden in these cases and participants were assigned to the scan group, with the opportunity to undergo a new
amyloid PET scan and results disclosure. This deviation did not impact the balance of the study groups (including the subgroups of amyloid positive
and negative cases) on key baseline characteristics or primary outcomesmeasures
time and their interaction, and random effects for participant, were
used to examine change in the dependent variables. Least squares
means and their corresponding standard errors were reported by
group and time point along with means and standard errors from
within-group linear contrasts. Linear mixed modeling was also used
to examine psychological safety by scan result. All 164 participants
were included and the significance level was set at P < .05 for two-
sided hypothesis testing. Results based on untransformed dependent
variables are reported as findings were similar using transformed
data.
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TABLE 1 Sample characteristics by study group
*


















































































































9.2 (1.59) 9.0 (1.96) 9.4 (1.06) 8.9 (2.50) 8.6 (2.65) 9.1 (2.35)
Mean UBACC score (SD) 18.9 (1.43) 18.9 (1.32) 18.9 (1.56) 19.1 (1.43) 18.8 (1.51) 19.3 (1.31)
Abbreviations: GED, general education diploma; MCI, mild cognitive impairment; PET, positron emission tomography; SD, standard deviation; UBACC, Uni-
versity of San Diego Brief Capacity to Consent.
aRating of interest in PET amyloid PET on 10-point scale.
*p type= >.05 difference between scan and comparison groups using chi-square or t-test; post-hoc comparisons of demographic characteristics of amyloid
negative and amyloid positive scan group participants were also non-significant
3 RESULTS
The sample included 164 individuals (n = 82 patients; n = 82 care-
givers) who completed baseline data collection before allocation to
the scan opportunity (n = 42 dyads) or comparison condition (n =
40 dyads). Characteristics of the sample are shown in Table 1. Most
patients were highly interested (M = 9.2 on a 10-point scale) in learn-
ing their brain amyloid status upon enrollment. Of the 39 scan group
patients who completed pre-test counseling, 37 proceeded with the
scan, and 36 received results. Reasons for declining included concerns
about radiation exposure and the potential for a negative emotional
reaction.
3.1 Primary outcomes
Among patient participants, there were no significant time or group by
time effects for any of the three primary endpoints (Table 2). Findings
were similar among caregivers. However, a time effect was observed
for objective knowledge of MCI/AD, with scores increasing from base-
line among caregivers in both groups (FT = 5.12, P = .002). A within
group time effect was observed for self-efficacy for coping with MCI;
caregivers in the scan group reported decreased self-efficacy for cop-
ing with their relatives’ MCI at 4 weeks post results disclosure (mean
difference = −12.35 ± −5.12; P < .05), with the decrease persisting at
week 52 (mean difference=−14.98±−6.67; P< .05).
3.2 Safety outcomes and subgroup analyses
Therewere no consistent differences in depressive symptoms in either
patients or caregivers, and patients’ ratings of state anxiety were sta-
ble over time across groups (Figure 2). Caregivers’ state anxiety lev-
els were increased from baseline at both 4 and 24 weeks of follow-up,
returning to baseline at week 52 (FT = 3.16, P = .031). Mean scores
on both the depression and anxiety measures were below cut-points
for clinical significance across all participant groupings and time points
(Table S1 in supporting information).
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FG = 0.00, P= .955
FT = 0.96, P= .412















FG = 0.00, P= .947
FT = 1.54, P= .207























FG = 1.64, P= .204
FT = 0.25, P= .863



















FG = 0.03, P= .871
FT = 5.12, P= .002
**























FG = 0.37, P= .543
FT = 0.14, P= .936

















FG = 0.04, P= .852
FT = 2.19, P= .100
FG×T = 1.33, P= .274
Abbreviations: IPQ, Illness PerceptionQuestionnaire; SE, standard error.
*P< .05.
**P< .01.
Subgroup analyses showed increasing perceived ambiguity about
MCI among amyloid negative patients (P < .05) and revealed that
decreased self-efficacy for coping was most pronounced among care-
givers of amyloid positive individuals at 4 weeks post disclosure (mean
difference = −14.83 ± 7.22; P <.05), and those of amyloid negative
patients at24weekspost disclosure (meandifference=−12.22±5.83;
P<.05).
At all follow-up assessments, IES ratings were higher among amy-
loid positive patients versus amyloid negative patients. These scores
declined over time (FT = 5.42, P =.008), but between group differ-
ences persisted (Figure 3). Similar patterns were observed on IGT-AD
distress ratings, with the greatest difference at week 4 at which amy-
loid positive patients had mean IGT-AD scores averaging three times
higher than amyloid negative patients. IGT-AD positive scores were
elevated and stable among amyloid positive patients but increased at
each follow-up point among amyloid negative patients, whose scores
grewcloser to thoseof theamyloidpositivepatients over time (see sup-
porting information).
Analyses of caregiver post-disclosuredistress revealed groupdiffer-
ences on the IGT-AD distress and positive subscales, with caregivers
of amyloid positive individuals reacting more negatively to test results
(Figure 3).
4 DISCUSSION
We hypothesized that, irrespective of scan results, having the oppor-
tunity to learn more about the potential etiology of cognitive symp-
toms would improve patients’ and caregivers’ overall understanding
of, and self-efficacy for coping with, MCI. However, learning one’s
brain amyloid status was no more effective than an MCI educa-
tion session for increasing caregivers’ knowledge about MCI, and
patients’ knowledge scores were unchanged regardless of group
assignment. Subgroup analysis showed that perceived ambiguity
regarding MCI increased in amyloid negative patients, suggesting
that such individuals likely understood that their symptoms remained
unexplained.
Contrary to our hypothesized increase, we observed decreased
self-efficacy for coping with MCI among caregivers of scan group
participants, a findingwhichwas present, at varying timepoints, among



























































F IGURE 2 Psychological safety. Measures of mood over time. CESD, Center for Epidemiological Studies Depression Scale; STAI, Speilberger
State Anxiety Inventory; Aβ, amyloid beta
caregivers of participants with both positive and negative results. This
unstable decrease in self-efficacy could potentially reflect feelings of
unpreparedness regarding theprospect of one’s relative progressing to
AD (amyloid-positive group) aswell as increased uncertainty about the
cause of the symptoms (amyloid-negative group).
Although emerging literature suggests that disclosing brain amy-
loid status to cognitively normal adults and those with subjective
cognitive impairment has no discernable effect on psychologi-
cal well-being, evidence in overtly symptomatic populations and
family caregivers is limited.17 Consistent with prior investigations
of unimpaired persons,18 we found no significant differences in
mood between amyloid positive and negative individuals. How-
ever, we observed significant and sustained levels of event-related
distress among MCI care dyads who learned of amyloid positivity,
with ratings notably higher than those reported in asymptomatic
samples.
Overall, our findings raise the possibility that emotional sup-
port interventions may be indicated upon biomarker testing in MCI,
although needs may vary depending on one’s perspective (patient or
caregiver) and scan result.
Given the self-selection bias associated with ADRC participation,
there is a critical need for additional studieswithmore diverse samples
whomaybe less receptive, ormay responddifferently, toADbiomarker
testing. Importantly, RAISR excluded individuals with active untreated
mood disorders, which are prevalent among cognitively impaired indi-
viduals. Therefore, our exploratory findings regarding psychological
safetymaynot extend to allMCI patientsmeetingAppropriateUseCri-
teria for amyloid PET.19,20
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FT=  5.42, p=0.008
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F IGURE 3 Post-disclosure impact of event scores over time. IES, Impact of Events Scale; IGT, Impact of Genetic Testing Scale; Aβ, amyloid beta.
An IES total score cut-off point of 26 is noted by a dashed line above which amoderate or severe impact may be indicated
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